Key Considerations for Reshoring U.S. Drug Manufacturing

Epstein Becker & Green
Contact
This Diagnosing Health Care episode dives into the key business operations and legal considerations for reshoring active pharmaceutical ingredient (or “API”) and finished drug product manufacturing to the United States. The episode features Members of the Firm Delia Deschaine and Neil Di Spirito and is hosted by attorney Bonnie Scott.

Here’s a preview of what you’ll hear:

• “The risk of FDA enforcement action that significantly disrupts the supply chain is, in fact, See more +

This Diagnosing Health Care episode dives into the key business operations and legal considerations for reshoring active pharmaceutical ingredient (or “API”) and finished drug product manufacturing to the United States. The episode features Members of the Firm Delia Deschaine and Neil Di Spirito and is hosted by attorney Bonnie Scott.

Here’s a preview of what you’ll hear:

• “The risk of FDA enforcement action that significantly disrupts the supply chain is, in fact, greater for companies that rely on foreign versus domestic entities.” —Delia Deschaine, Member of the Firm

• “Development and integration of technology, like continuous manufacturing and 3D printing, would be necessary to effectively make reshoring feasible.” —Neil Di Spirito, Member of the Firm

• “There's also this need for balance, likely some sort of hybrid model, where U.S. production may be ramped up to help bolster supply, but we would still lean on foreign manufacturers for many of the same reasons offshoring has been so appealing to date.” —Bonnie Scott, Associate

The Diagnosing Health Care podcast series examines the business opportunities and solutions that exist despite the high-stakes legal, policy, and regulatory issues that the health care industry faces.

See less -

Embed
Copy

Other MultiMedia by Epstein Becker & Green

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Epstein Becker & Green | Attorney Advertising

Written by:

Epstein Becker & Green
Contact
more
less

Epstein Becker & Green on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.